A Phase 2 Study of Elotuzumab (Elo) in Combination with Lenalidomide and Low-Dose Dexamethasone (Ld) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (R/R MM): Updated Results

被引：1

作者：

Richardson, Paul G. ^{[1
]}

Jagannath, Sundar ^{[2
]}

Moreau, Philippe ^{[3
]}

Jakubowiak, Andrzej ^{[4
]}

Raab, Marc S. ^{[5
,6
]}

Facon, Thierry ^{[7
]}

Vij, Ravi ^{[8
]}

White, Darrell J. ^{[9
]}

Reece, Donna ^{[10
]}

Benboubker, Lotfi ^{[11
]}

Zonder, Jeffrey A. ^{[12
]}

Deng, Wei ^{[13
]}

Kroog, Glenn ^{[14
]}

Singhal, Anil K. ^{[13
]}

Lonial, Sagar ^{[15
]}

机构：

[1] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA

[2] Mt Sinai Med Ctr, New York, NY 10029 USA

[3] Univ Hosp Hotel Dieu, Dept Hematol, Nantes, France

[4] Univ Chicago, Med Ctr, Chicago, IL 60637 USA

[5] Heidelberg Univ, Med Ctr, Heidelberg, Germany

[6] German Canc Res Ctr, Heidelberg, Germany

[7] Hop Claude Huriez, Serv Malad Sang, Lille, France

[8] Washington Univ, Sch Med, St Louis, MO USA

[9] Queen Elizabeth 2 Hlth Sci Ctr, Div Hematol, Halifax, NS, Canada

[10] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada

[11] Hop Bretonneau, Ctr Reg Cancerol Henry Kaplan CHRU Tours, Serv Hematol & Therapies Cellulaires, Tours, France

[12] Barbara Ann Karmanos Canc Inst, Detroit, MI USA

[13] Abbott Biotherapeut Corp, Redwood City, CA USA

[14] Bristol Myers Squibb Co, Princeton, NJ USA

[15] Emory Univ, Div BMT, Winship Canc Inst Hematol & Med Oncol, Atlanta, GA 30322 USA

来源：

BLOOD | 2012年 / 120卷 / 21期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

202

引用

下载

页数：2

共 50 条

[21] A randomized phase II study of bortezomib (Btz)/dexamethasone (dex) with or without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
Jakubowiak, Andrzej J.
Offidani, Massimo
Pegourie, Brigitte
De La Rubia, Javier
Garderet, Laurent
Laribi, Kamel
Bosi, Alberto
Marasca, Roberto
Laubach, Jacob
Mohrbacher, Ann
Carella, Angelo Michele
Singhal, Anil K.
Tsao, Claire
Lynch, Mark John
Bleickardt, Eric W.
Jou, Ying-Ming
Palumbo, Antonio
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[22] Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in High-Risk and/or Stage 2-3 Relapsed and/or Refractory Multiple Myeloma: A Retrospective Subset Analysis of the Phase 2 Study
Jagannath, Sundar
Lonial, Sagar
Jakubowiak, Andrzej J.
Facon, Thierry
Vij, Ravi
Raab, Marc S.
White, Darrell J.
Wang, Min-Hui
Parli, Teresa
Bartlett, Blake J.
Singhal, Anil K.
Richardson, Paul G.
BLOOD, 2011, 118 (21) : 1697 - 1698
[23] ELOQUENT-2: A phase III, randomized, open-label study of lenalidomide (Len)/dexamethasone (dex) with/without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
Lonial, Sagar
Dimopoulos, Meletios A.
Palumbo, Antonio
White, Darrell
Grosicki, Sebastian
Spicka, Ivan
Walter-Croneck, Adam
Moreau, Philippe
Mateos, Maria-Victoria
Magen-Nativ, Hila
Belch, Andrew
Reece, Donna Ellen
Beksac, Meral
Taniwaki, Masafumi
Roellig, Christoph
Singhal, Anil K.
Katz, Jessica
Bleickardt, Eric W.
Poulart, Valerie
Richardson, Paul G.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[24] Phase II study of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with relapsed or relapsed and refractory multiple myeloma (MM)
Anderson, K. C.
Jagannath, S.
Jakubowiak, A.
Lonial, S.
Raje, N.
Schlossman, R.
Munshi, N.
Knight, R.
Esseltine, D.
Richardson, P. G.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[25] LENALIDOMIDE IN COMBINATION WITH LOW-DOSE DEXAMETHASONE IN RELAPSE/ REFRACTORY MULTIPLE MYELOMA: A RETROSPECTIVE STUDY
Firatli-Tuglular, T.
Noyan-Atalay, F.
Eser, A.
Toptas, T.
Pepedil, F.
Kaygusuz-Atagunduz, I.
Adiguzel, C.
HAEMATOLOGICA, 2013, 98 : 614 - 615
[26] A Phase 1 and 2 Study of Filanesib Alone and in Combination With Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma
Shah, Jatin J.
Kaufman, Jonathan L.
Zonder, Jeffrey A.
Cohen, Adam D.
Bensinger, William I.
Hilder, Brandi W.
Rush, Selena A.
Walker, Duncan H.
Tunquist, Brian J.
Litwiler, Kevin S.
Ptaszynski, Mieke
Orlowski, Robert Z.
Lonial, Sagar
CANCER, 2017, 123 (23) : 4617 - 4630
[27] Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study
Richardson, Paul G.
Siegel, David S.
Vij, Ravi
Hofmeister, Craig C.
Baz, Rachid
Jagannath, Sundar
Chen, Christine
Lonial, Sagar
Jakubowiak, Andrzej
Bahlis, Nizar
Song, Kevin
Belch, Andrew
Raje, Noopur
Shustik, Chaim
Lentzsch, Suzanne
Lacy, Martha
Mikhael, Joseph
Matous, Jeffrey
Vesole, David
Chen, Min
Zaki, Mohamed H.
Jacques, Christian
Yu, Zhinuan
Anderson, Kenneth C.
BLOOD, 2014, 123 (12) : 1826 - 1832
[28] A PHASE 2 MULTICENTER STUDY OF POMALIDOMIDE IN COMBINATION WITH LOW-DOSE DEXAMETHASONE IN JAPANESE PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA: THE MM-011 TRIAL
Hagiwara, S.
Okamoto, S.
Matsue, K.
Iida, S.
Sunami, K.
Komeno, T.
Suzuki, K.
Ando, K.
Taniwaki, M.
Tobinai, K.
Chou, T.
Kaneko, H.
Iwasaki, H.
Uemura, C.
Tamakoshi, H.
Zaki, M. H.
Doerr, T.
Kuroda, Y.
Ichinohe, T.
HAEMATOLOGICA, 2016, 101 : 790 - 790
[29] Dasatinib in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma: Preliminary Results of a Phase I Study
Facon, Thierry
Leleu, Xavier
Stewart, A. Keith
Spencer, Andrew
Rowlings, Philip
Hulin, Cyrille
Attal, Michel
Garzon, Felix
Bleickardt, Eric
Gialelis, Konstantina
Tuozzoli, Doreen
Derreumaux, Dorninique
Sonneveld, Pieter
BLOOD, 2009, 114 (22) : 744 - 745
[30] A Phase II Study of Pegylated Liposomal Doxorubicin (PLD), Bortezomib, Dexamethasone and Lenalidomide (DVD-R) for Patients with Relapsed/Refractory (R/R) Multiple Myeloma (MM)
Berenson, James R.
Yellin, Ori
Cartmell, Alan D.
Woliver, Thomas B. S.
Flam, Marshall S.
Nassir, Youram
Vescio, Robert
Swift, Regina A.
BLOOD, 2010, 116 (21) : 1254 - 1255

← 1 2 3 4 5 →